Oslo, 26 June 2013 - PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that both the temporary paused intra-tumour part of the head & neck cancer study and the bile duct cancer study are open for inclusion and actively screening for patients.
Head & Neck cancer
Patient inclusion in the ENHANCE study in head & neck cancer patients has been paused for patients with deeper tumours requiring intra-tumour illumination. The intra-tumour illumination procedure will be optimized in a separate part of the study, running in parallel to the open inclusion of patients for superficial illumination. The intra-tumour part of the study will be performed at selected hospitals with extensive experience with photodynamic therapy, with The Netherlands Cancer Institute (NKI) in Amsterdam as the coordinating site. NKI and University College Hospital in London are currently open for inclusion and actively screening for patients for the intra-tumour part of the study. The first patient is expected to be included shortly.
Bile Duct cancer
Preparations for a Proof of Concept study for the use of PCI in patients with bile duct cancer is progressing as planned. The company has received all necessary approvals from the authorities and ethics committee in the UK and Germany, and two hospitals in Germany are currently open for inclusion and actively screening for patients. The first patient is expected to be included shortly.
Contact information:
PCI Biotech Holding ASA, Strandveien 55, N-1366 Lysaker
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429
Bernt-Olav Røttingsnes, CFO, bor@pcibiotech.no, Mobile: +47 913 47 021